Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ANL NASDAQ:DBVT NASDAQ:LXEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.80+1.4%$1.94$0.87▼$6.37$283.39M0.99857,757 shs667,800 shsANLAdlai Nortye$1.71+0.6%$1.59$1.10▼$3.89$63.14M-0.9511,243 shs11,335 shsDBVTDBV Technologies$9.40+8.0%$9.84$2.20▼$12.78$257.51M-0.36190,902 shs23,670 shsLXEOLexeo Therapeutics$5.19-1.1%$4.55$1.45▼$11.72$280.26M1.36623,976 shs415,424 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-8.31%+17.45%+28.37%+73.58%-43.09%ANLAdlai Nortye-2.86%+0.59%+7.94%+4.23%-22.73%DBVTDBV Technologies-4.08%-8.88%-11.11%-3.01%+118.20%LXEOLexeo Therapeutics+4.58%+9.60%+15.89%+13.88%-51.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.80+1.4%$1.94$0.87▼$6.37$283.39M0.99857,757 shs667,800 shsANLAdlai Nortye$1.71+0.6%$1.59$1.10▼$3.89$63.14M-0.9511,243 shs11,335 shsDBVTDBV Technologies$9.40+8.0%$9.84$2.20▼$12.78$257.51M-0.36190,902 shs23,670 shsLXEOLexeo Therapeutics$5.19-1.1%$4.55$1.45▼$11.72$280.26M1.36623,976 shs415,424 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-8.31%+17.45%+28.37%+73.58%-43.09%ANLAdlai Nortye-2.86%+0.59%+7.94%+4.23%-22.73%DBVTDBV Technologies-4.08%-8.88%-11.11%-3.01%+118.20%LXEOLexeo Therapeutics+4.58%+9.60%+15.89%+13.88%-51.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1748.81% UpsideANLAdlai Nortye 2.00Hold$9.00426.01% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7556.91% UpsideLXEOLexeo Therapeutics 3.00Buy$15.33195.44% UpsideCurrent Analyst Ratings BreakdownLatest ANL, ALEC, LXEO, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.008/15/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $9.007/31/2025LXEOLexeo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.506/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M2.82N/AN/A$1.29 per share2.17ANLAdlai Nortye$5M12.63N/AN/A$0.69 per share2.48DBVTDBV TechnologiesN/AN/AN/AN/A$1.42 per shareN/ALXEOLexeo Therapeutics$650K431.17N/AN/A$3.53 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)ANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/ADBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)Latest ANL, ALEC, LXEO, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78ANLAdlai Nortye0.021.411.41DBVTDBV TechnologiesN/A2.452.45LXEOLexeo TherapeuticsN/A4.434.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ANLAdlai Nortye35.21%DBVTDBV Technologies71.74%LXEOLexeo Therapeutics60.67%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%ANLAdlai NortyeN/ADBVTDBV Technologies1.44%LXEOLexeo Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionableANL, ALEC, LXEO, and DBVT HeadlinesRecent News About These CompaniesVestal Point Capital LP Cuts Stock Position in Lexeo Therapeutics, Inc. $LXEOSeptember 4, 2025 | marketbeat.comIs Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?August 29, 2025 | finance.yahoo.comAffinity Asset Advisors LLC Acquires Shares of 1,480,881 Lexeo Therapeutics, Inc. $LXEOAugust 28, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from AnalystsAugust 27, 2025 | marketbeat.comWhat is Chardan Capital's Forecast for LXEO FY2025 Earnings?August 23, 2025 | marketbeat.comInsider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of StockAugust 21, 2025 | insidertrades.comLexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy DesignationAugust 20, 2025 | msn.comLexeo Therapeutics (NASDAQ:LXEO) Given New $15.00 Price Target at Chardan CapitalAugust 17, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Announces Earnings ResultsAugust 17, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Given New $9.00 Price Target at HC WainwrightAugust 17, 2025 | marketbeat.comLexeo Therapeutics price target lowered to $15 from $20 at ChardanAugust 16, 2025 | msn.comLexeo Therapeutics reports Q2 EPS (60c) vs (64c) last yearAugust 14, 2025 | msn.comLexeo Therapeutics Appoints New Chief Financial OfficerAugust 14, 2025 | tipranks.comLexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 14, 2025 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) Shares Up 1.8% - What's Next?August 10, 2025 | marketbeat.comOppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform RecommendationAugust 1, 2025 | msn.comStifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)July 29, 2025 | msn.comLexeo Therapeutics Holds 2025 Annual Stockholders MeetingJuly 25, 2025 | theglobeandmail.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - MorningstarJuly 8, 2025 | morningstar.comMLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - NasdaqJuly 8, 2025 | nasdaq.comWhy Lexeo Is Rising In Pre-market? - NasdaqJuly 8, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?By Leo Miller | August 13, 2025ANL, ALEC, LXEO, and DBVT Company DescriptionsAlector NASDAQ:ALEC$2.80 +0.04 (+1.45%) Closing price 04:00 PM EasternExtended Trading$2.79 -0.01 (-0.32%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Adlai Nortye NASDAQ:ANL$1.71 +0.01 (+0.65%) Closing price 03:57 PM EasternExtended Trading$1.73 +0.02 (+1.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.DBV Technologies NASDAQ:DBVT$9.20 +0.50 (+5.69%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Lexeo Therapeutics NASDAQ:LXEO$5.19 -0.06 (-1.14%) Closing price 04:00 PM EasternExtended Trading$5.31 +0.12 (+2.31%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
